The original Chinese medicine for the treatment of alzheimer's disease has been approved for listing and has been pleasantly surprised by the clinician. Alzheimer's disease, which is one of the most common types of senile dementia, is a central nervous system.
Among the commemorative stamps of "scientific and technological innovation II" issued by China Post on November 1, the fourth is the new drug gv-971 for Alzheimer's disease treatment. Photo source: released in Shanghai
Statistics show that at least 50 million people with Alzheimer's disease worldwide are currently suffering from Alzheimer's disease, with an explosive increase, which is expected to reach 150 million by 2050. In China, Alzheimer's disease has more than 10 million people, ranking first in the world, with an annual increase of more than 300000 new cases.
Dr. Deng Yulei, neurology department of Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, said in an interview with surging journalists that Alzheimer's disease has attracted great social attention now, and people's attention to the disease is also increasing year by year. "Ruijin Hospital opened a special outpatient service for memory disorders as early as the 1990s. At that time, we came to see that Many patients can't take care of themselves or even don't know their families, but now many patients in the early stage of the disease find that memory is lower than before, they will come to see a doctor immediately. "
Deng Yulei said that with the development of aging, the age of Alzheimer's disease has expanded from about 50 to 60 years old to 60 to 90 years old, especially among people over 80 years old, and the incidence of Alzheimer's disease is increasing year by year.
"From the symptoms of this disease, memory decline is the most common clinical manifestation, in addition to the decline of language function and spatial recognition function, which is easy to lead to patients lost or lost, and some of them are poor logic ability, even personality changes, which are easy to be ignored, in fact, this is part of the symptoms of Alzheimer's disease." Deng said.
Because the pathogenesis is not clear, there have been clinical treatment difficulties in the treatment of Alzheimer's disease for many years. "there are two main types of drugs in the existing clinical treatment, one is cholinesterase inhibitor, such as Donepazil, carbalastine tartrate, and the other is NMDA receptor coordinator, such as Mejingang Hydrochloride, but these three drugs still can not block or reverse the disease and can only relieve the symptoms. There has been no new progress in the development of new drugs for Alzheimer's disease in 17 years, and drugs such as Mejingang have been on sale abroad in the late 1990s. "
Why is it difficult to develop new drugs? Deng Yulei pointed out that this is mainly because the pathogenesis of Alzheimer's disease is still unclear. "Only by finding the pathogenesis can we block the progress of the disease and significantly improve the symptoms. At present, the etiology includes heredity, trauma, history of encephalitis and so on. It may also be related to spirit and emotion. The etiology is very complex. It can be seen that its treatment also needs multi angle and multi-target clinical research. "
The advent of Mannose-sodium capsules (GV-971) has led to the hope that the drug has conducted a multi-center clinical study in China, with 818 patients enrolled in Phase III clinical trials in 34 locations in China.
The Ruijin hospital team also participated in the clinical study, Deng said: "this study mainly adopts double-blind, placebo-controlled study, as a new drug, after half a year of clinical verification, it can significantly improve the cognitive dysfunction of patients. We just learned that "nine phase one" was approved by the State Food and Drug Administration on November 2, 2019, and can be applied to patients with mild to moderate Alzheimer's disease. As a clinician, we look forward to adding a powerful weapon in the fight against Alzheimer's disease. "